ClinicalTrials.gov
ClinicalTrials.gov Menu

Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01512043
Recruitment Status : Completed
First Posted : January 19, 2012
Last Update Posted : May 6, 2014
Sponsor:
Collaborators:
University of Oslo
Norwegian Foundation for Health and Rehabilitation
University of Bergen
Information provided by (Responsible Party):
Lovisenberg Diakonale Hospital

Brief Summary:
There is a demand for explorative and comparative studies on various non-pharmaceutical efforts in treating and helping chronic obstructive pulmonary disease patients. This study has been developed in light of this need. The main purpose of the project is to test whether a device guided breathing control system can decreasing the feeling of breathlessness in patients with moderate stage and severe stage of COPD. In addition the study could shed light on whether a reduced feeling of breathlessness can lead to improved physical function, and less experience of other symptoms (I.e., depression, anxiety, sleeping difficulties, fatigue, pain) and provide a better quality of life for patients with COPD.

Condition or disease Intervention/treatment Phase
COPD Behavioral: Breathing control Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD) Intervention With Device-guided Breathing Control in COPD
Study Start Date : July 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: 1. Breathing control
Description ...
Behavioral: Breathing control
Practice of device guided breathing control twice a day for four weeks.

Active Comparator: 2. Listening to music
Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
Behavioral: Breathing control
Practice of device guided breathing control twice a day for four weeks.

Sham Comparator: 3. Silence
Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
Behavioral: Breathing control
Practice of device guided breathing control twice a day for four weeks.




Primary Outcome Measures :
  1. Breathlessness [ Time Frame: 4 months ]
    Questionnaires


Secondary Outcome Measures :
  1. Depression [ Time Frame: 4 months ]
    Questionnaires

  2. Pulmonary functional tests [ Time Frame: 4 months ]
  3. Anxiety [ Time Frame: 4 months ]
    Questionnaires

  4. Fatigue [ Time Frame: 4 months ]
    Questionnaire

  5. Sleeping difficulties [ Time Frame: 4 months ]
    Questionnaires

  6. Pain [ Time Frame: 4 months ]
    Questionnaire

  7. 6. Min walk test [ Time Frame: 4 months ]
  8. Arterial blood gas measures [ Time Frame: 4 months ]
  9. Quality of life [ Time Frame: 4 months ]
    Questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Dyspnoea symptoms in daily life
  • Spirometry values showing a COPD moderate stage II (FEV1/FVC<70%, FEV1<80%) and severity grade at a severe stage III (FEV1/FVC<70%, FEV1<50% and FEV1 = 30% of a predicted)
  • Be able to read, write and speak Norwegian
  • Be at a stable phase of the disease

Exclusion Criteria:

  • Changes in pulmonary medication during the last 4 weeks
  • Diagnosis of cancer
  • Presently attending a pulmonary rehabilitation course or other similar COPD education courses (due to the fact that these courses often have instructions on breathing control), or having attended similar courses during the last six months
  • Ongoing exacerbation
  • Attending other competitive studies
  • Diagnosis of neuromuscular disease
  • Diagnosis of dementia
  • Attending help from a pulmonary physiotherapist

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01512043


Locations
Norway
Lovisenberg Diakonale Hospital
Oslo, Norway, 0440
Sponsors and Collaborators
Lovisenberg Diakonale Hospital
University of Oslo
Norwegian Foundation for Health and Rehabilitation
University of Bergen
Investigators
Principal Investigator: Astrid K Wahl, Professor University of Oslo

Responsible Party: Lovisenberg Diakonale Hospital
ClinicalTrials.gov Identifier: NCT01512043     History of Changes
Other Study ID Numbers: 2009/2/0285
First Posted: January 19, 2012    Key Record Dates
Last Update Posted: May 6, 2014
Last Verified: May 2014

Keywords provided by Lovisenberg Diakonale Hospital:
Breathlessness
Symptoms
Quality of life

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases